Anti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3<sup>+</sup> T<sub>reg</sub> population.

Nat Commun · 2024 · PMC11686037 · PMID 39737964

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Even though these results did not withstand a correction of multiple comparison, a clear trend was visible.

also in 19,460 other papers

highly significantno p-value reported

Only 2.9% of the patients receiving anti-CTLA4 treatment post-LAD developed lymphedema, indicating a highly significant effect of anti-CTLA4 monotherapy in preventing lymphedema.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Anti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3&lt;sup&gt;+&lt;/sup&gt; T&lt;sub&gt;reg&lt;/sub&gt; population.

The sentences

Anti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3<sup>+</sup> T<sub>reg</sub> population.